Type segment insights:

Type-wise, the standard category of sodas is the carbonated soft drink flavor, which has the biggest market share. However, with increasing awareness about the harmful effects of high sugar intake, consumers have started to decrease their soda consumption and shifted to diet and lower calorie variants of the same. Therefore, the share of diet carbonated drinks is expected to witness significant growth during the forecasted period. Fruit-flavored carbonated drinks are also very popular, with continued demand for flavors like lime-lemon and orange as refreshing drinks.

Sales channel segment insights:

Among the various sales channels for carbonated soft drinks, the hypermarkets, supermarkets, and general merchandisers segment dominated the market with a 40% share in 2018. However, it is expected to lose some ground to channels like food service and drinking establishments, convenience stores and gas stations, as well as online grocery shopping portals. The rising demand for high value, naturally-made soft drinks in exotic flavors, is expected to drive the inclusion of such premium drinks in the menus of restaurants across the world.

Regional insights:

North America is leading the way with regard to health consciousness, with many soft drink manufacturers participating in aggressive innovation in the low-sugar and no-calorie segment of the carbonated beverages market. Europe held approximately 34% of the global market in 2018, followed by the North American region with a 28% share. In the North American and European regions, the sale of carbonated beverages has experienced slower growth. Nonetheless, sales values have increased, especially in Europe, owing to the increased sale of premium and high-value products. Asia-Pacific, experiencing high urbanization, is anticipated to expand at the highest CAGR (5.8%) during the forecasted period. The Latin America, and the Middle East and Africa markets too are poised for growth.

Companies covered:

1. The Coca-Cola Company
2. PepsiCo Inc.
3. Dr Pepper Snapple
4. Cott Corporation
5. Asahi Soft Drinks
6. National Beverage Corp.
7. F&N Foods
8. Britvic PLC
9. Parle Agro

Customizations available

The post Global Carbonated Beverage Market (2018 – 2023) first appeared on CRI Report.

Product type insights:

There are seven types of gluten-free food: bakery food, dairy food, meat and its substitutes, pasta, condiments, spices and spreads, desserts and ice cream, and ready-to-eat meals. The gluten-free bakery food segment held the largest share of the market (29%) in 2018, owing to the high global demand for gluten-free bread, buns, and rolls. This segment is forecast to expand at a CAGR of 8.5% over 2018–2023.

Regional insights:

Europe is estimated to be on track to record the highest CAGR (10.3%) during the forecasted period, sustained by changing consumer perceptions about the effects of gluten-free diets, such as weight loss and good health. North America held the largest market share (53%) in 2018, underpinned by the rising number of patients diagnosed with celiac disease.

Distribution channel segment insights:

The common distribution channels for the market are conventional stores, specialty stores, and drug stores. Conventional retailers include grocery stores, club stores, and mass merchandisers. Among the different distribution channels, conventional stores held the highest market share (83%), given their ease of accessibility.

Companies covered:

1. Kraft Heinz Company
2. Conagra Brands, Inc.
3. General Mills, Inc.
4. Kellogg Company
5. Dr. Schar AG/SPA
6. Hain Celestial Group, Inc.
7. Doves Farm

Customizations available

The post Global Gluten-Free Food Market (2018-2023) first appeared on CRI Report.

Customizations available

The post Global Telehealth Market (2018-2023) first appeared on CRI Report.

Application segment insights:

Advancements in digital technologies such as machine learning, machine vision, and motion control, have led to the higher adoption of industrial automation in several sectors, with greater prominence in the automotive sector. The industrial automation segment occupied the largest market share (49%) globally, in 2017, followed by the Industrial Internet of Things (IIoT) (33%). A concerted effort by the industrial sectors and technology firms have resulted in innovative solutions to cater to IIoT. Smart factories have also shown steady growth, brought about by 3D printing and distributed manufacturing control systems.

End users segment insights:

The highest adoption of smart manufacturing is expected in the aerospace sector, which will expand at a CAGR of 25% during the forecasted period. This is fuelled by the increased production of advanced aircraft, such as the Boeing 787 and Airbus A350. Increased use of robots in industrial control mechanisms will drive the automotive and industrial equipment end users segment, at CAGRs of 15.6% and 11.2% respectively, during the 2018-2023 period. The chemicals and materials, food and agriculture, and healthcare sectors are also some of the promising areas for the implementation of smart manufacturing technologies.

Regional insights:

North America is leading the innovation in the smart manufacturing market, and occupied approximately 27% of the global market in 2017. Massive investments in smart manufacturing technologies, tax subsidies for manufacturers, and innovations in robotics have fuelled the growth of the smart manufacturing market in the region. Asia-Pacific, experiencing high industrialization, occupied a 25% share in 2017. The Latin America and the Middle East and Africa markets though, still at nascent stages, are experiencing decent growth.

Companies covered:

1. KUKA
2. ABB Ltd
3. Cisco Systems, Inc.
4. IBM Security
5. The Raytheon Company
6. Stratasys, Ltd.
7. The Emerson Electric Co.
8. Alpine Data Labs
9. SAP SE
10. Maersk

Customizations available

The post Global Smart Manufacturing Market (2018-2023) first appeared on CRI Report.

Diagnostic techniques segment insights:

Liver biopsy is one of the broadly accepted diagnostic techniques for NASH detection since it provides accurate results. Liver biopsy is preferred by medical practitioners owing to its ability to determine the degree of steatosis and inflammation accurately. However, the invasive liver biopsy procedure has several disadvantages, such as pain, bleeding, and the possibility of injuring other organs. Thus, the adoption of non-invasive imaging techniques and biomarkers is anticipated to increase significantly. As a result, the market size of the liver biopsy technique is expected to grow at a slower rate than biomarkers, in developed regions like North America and Europe.

Regional insights:

North America held the largest share of the NASH diagnostics market. The growing prevalence of obesity and type 2 diabetes is leading to an increasing number of patients suffering from NASH in the United States (U.S.) and Canada. NASH has been reported to be the second-most common cause for liver transplantations in the U.S. By 2020, it is expected to surpass hepatitis C as the leading cause for liver transplants. Asia-Pacific is expected to be the fastest growing market owing to increasing awareness among patients and improving healthcare infrastructure. However, the high cost of NASH diagnosis through liver biopsy is restraining the growth of the market in developing regions like Latin America and Asia-Pacific.

Companies covered:

1. GENFIT SA
2. Echosens
3. SuperSonic Imagine
4. BioPredictive
5. One Way Liver, S.L. (OWL)
6. VLVbio AB
7. Quest Diagnostics Incorporated
8. Prometheus Laboratories Inc.
9. Siemens Healthcare GmbH.
10. Exalenz Bioscience Ltd.

Customizations available

The post Global Non-alcoholic Steatohepatitis (NASH) Diagnostics Market (2018-2023) first appeared on CRI Report.

Treatment mode segment insights:

The thermal ablation segment dominated the market, accounting for a 63.0% share of the global revenue in 2017. Rising adoption of minimally invasive procedures with reduced recovery periods is expected to fuel the demand for thermal ablation, including radiofrequency ablation and endovenous laser therapy, over the next few years. Furthermore, attractive reimbursement policies and recommendations by the United States (U.S.) American Venous Forum guidelines and the U.K. National Institute for Health and Care Excellence guidelines in favour of the thermal ablation process has resulted in spurring demand.
Endovenous non-thermal ablation is expected to be the fastest growing segment, increasing exponentially from 2018 to 2023 at a CAGR of 40.3%. Reduced risk of complications is projected to fuel the acceptance of this non-tumescent process over thermal ablation and other conventional treatment processes. The market share of the stripping treatment method is expected to decline considerably, owing to post-operative complications like infections at the incision sites, heavy bleeding, blood clots, bruising or scarring, and nerve injury.

End user segment insights:

The hospital segment garnered the largest share in 2017, followed by surgical clinics and specialized clinics. The availability of experienced medical professionals, coupled with favorable medical insurance policies has driven the demand for varicose veins treatment at hospitals. This segment held a 55.8% share of the global revenue in 2017.
The specialized clinics segment, which includes dedicated clinics for varicose veins treatment, is projected to witness a robust growth of 18.0% from 2018 till 2023. Patients, especially those from developed economies, are anticipated to propel the demand for treatment at specialized clinics during the forecast period. Adequate availability of cutting-edge, minimally invasive treatment procedures is predicted to drive the growth of this segment.

Regional insights:

North America was the largest regional segment, accounting for a 45.3% share of the global revenue in 2017. A growing geriatric population, obesity, and sedentary lifestyle in countries such as the U.S. and Canada, have resulted in the increased prevalence of varicose veins. Advanced healthcare infrastructure, coupled with favorable reimbursement policies have driven demand in this region in the past couple of years.
Europe was the second-leading regional segment in 2017, followed by Asia-Pacific. The market share of the Asia-Pacific region is expected to expand at the highest CAGR of 20.3% during the 2018-2023 period, owing to increased awareness among patients, along with rising healthcare expenditure. Countries like China, India, Japan, and South Korea are likely to experience significant growth over the next few years, owing to the prospects of the growing medical tourism industry, and a large patient pool.

Companies covered:

1. AngioDynamics, Inc.
2. Syneron Medical Ltd.
3. Vascular Insights, LLC
4. Biolas Health, Inc.
5. Energist Ltd.
6. Medtronic plc
7. BTG plc
8. Alma Lasers, Inc.
9. Lumenis Ltd.

Customizations available

The post Global Varicose Veins Market (2018-2023) first appeared on CRI Report.

Technology segment insights:

The clinical biochemistry segment dominated the market, accounting for 32.3% of the global revenue in 2017. Rising use of clinical chemistry analyzers, glucose monitoring, and blood gas and electrolyte analysis has fuelled the demand for clinical biochemistry-based diagnostics.
Immunodiagnostics is anticipated to be the fastest growing technology segment of the market, expanding at a booming CAGR of 10.1% during 2018-2023. The prevalence of animal-transmitted diseases has increased considerably, which in turn, has driven the demand for diagnostic tests that can quickly and efficiently detect pathogens. As a result, the demand for immunodiagnostics, including enzyme-linked immunosorbent assay (ELISA), immunoassay, and lateral flow assays, has increased rapidly.

Animal type segment insights:

The companion animal segment accounted for the largest share (52.5%) of the global revenue in 2017, and the market is estimated to grow at a steady rate during the forecast period. Pet ownership has increased considerably in the past few years, especially in North America and Europe. In the U.S., the number of companion animals increased to 211.8 MN in 2017, from 157.15 in 2012. Furthermore, pet industry expenditure in the U.S. reached USD 69.51 Bn in 2017, from USD 53.33 Bn in 2012. As a result, growth in pet ownership, coupled with increased spending on pet healthcare, especially in developed economies, has propelled the demand for veterinary diagnostics.

Products segment insights:

Consumables appeared to be the largest products segment in 2017, and is estimated to continue leading, accounting for an anticipated 34.9% share of the global market by 2023. Substantial demand from the developed countries of North America and Europe contributed to the considerable share of this segment during the past few years.

End user segment insights:

In terms of end users, point of care is anticipated to be the fastest growing segment during the forecast period. It is expected to register a steady CAGR of 9.4% during the 2018-2023 period. The development of low-cost and portable instruments with advanced functions has accelerated the growth of point of care diagnostics.

Regional insights:

North America held the largest share of the veterinary diagnostics market in 2017, owing to increased awareness about the harmful effects of zoonotic diseases. Also, increased spending by pet owners to improve pet health and increase the lifespan of pets has driven demand in North America, especially in the companion animal segment. Availability of attractive pet insurance policies has played a key role in driving the market in countries like the U.S. and Canada. The Asia-Pacific region is expected to exhibit the highest CAGR (10.9%) during the 2018-2023 period. Substantial growth in farm animal population, especially in China and India, is likely to propel market growth over the forecast period.

Companies covered:

1. IDEXX laboratories, Inc.
2. Zoetis Inc.
3. HESKA Corporation
4. Biolas Health, Inc.
5. Abaxis, Inc.
6. Neogen Corporation
7. QIAGEN
8. bioMérieux SA
9. Thermo Fisher Scientific, Inc.
10. Virbac
11. Randox Laboratories Ltd.
12. IDvet

Customizations available

The post Global Veterinary Diagnostics Market (2018-2023) first appeared on CRI Report.

Product Segment Insights:

1. Diesel Generator: The diesel generator market is anticipated to expand at a CAGR of 8.1%. The telecom industry is the key driver for diesel generators, occupying more than 40% of the installed base. The construction and hospitality industries come next in line. For businesses such as financial services where power outages can lead to wide-scale disruptions in the enterprise-wide management services, relying on uninterrupted power to run critical information systems has become mandatory.

2. UPS: The UPS market is expected to expand to INR 99.83 Bn in 2023, at a CAGR of 11.97%. Growing investments in IT and the rapid development of the IT sector have contributed to the boom in the UPS market. Increasing consciousness about the need to protect important data is benefiting the market. Domestic manufacturers are expected to witness stiff competition from foreign players. Manufacturers operating in the industry are emerging as a complete solution provider rather than mere suppliers.

3. Inverter: The inverter market is expected to expand to INR 277.83 Bn in 2023, at a CAGR of 9.33%. Growth in the inverter market can be attributed to the demand for power backup solutions across residential, commercial as well as industrial sectors. Moreover, the government’s initiatives to expand electrification rate in India coupled with technological developments is further expected to influence Indian inverter market in the coming years positively.

Companies Covered

1. Cummins India Limited
2. Su-Kam Power System Limited
3. Exide Industries Limited
4. Honda Siel Power Products Limited
5. Mahindra & Mahindra Limited
6. Kirloskar Oil Engines Limited
7. Amara Raja Batteries Limited
8. Microtek International Pvt. Ltd.
9. Luminous Power Technologies
10. Ashok Leyland

Customisation Available

The post Power Backup Market in India (2018-2023) first appeared on CRI Report.

Product type segment insights:

The scaffold-based 3D cell culture product segment is dominating the market and will continue to do so during the forecast period. This variant will occupy a market share of 36.6% among all the other product types by 2023. This high share is mainly attributed to the ability of scaffold-based products to impersonate in vivo conditions for the cell culture, thereby driving their adoption among researchers.

Application segment insights:

Depending on applications, the 3D cell culture market is segmented into drug discovery and toxicology, cancer research, and stem cell research/regenerative medicine. The cancer research sub-segment held the largest market share of about 42.8% in the year 2017. This is mainly attributed to the advantages offered by 3D cell culture over its 2D counterpart, growing number of cancer related researches, and funding initiatives across the globe. 3D cultures of cancer cells can generate new drug candidates for a researcher before moving to expensive and time-consuming animal models. 3D cell culture can speed discovery and save money involved in developing cancer models for preclinical screening and testing, as well as for the research and development (R&D) of new therapies.

End users segment insights:

3D cell culture is used across multiple end user segments, such as biotechnology and pharmaceutical companies, contract research laboratories, and academic institutes. Among these, the biotechnology and pharmaceutical companies dominated the market with a revenue of USD 0.77 Bn and 67% market share in 2017. This is primarily due to rising adoption of 3D cell culture as a new tool in early drug discovery, as well as potential treatment of diseases. Furthermore, rising need to continuously improve the productivity of pharmaceutical R&D is further accelerating implementation of 3D cell cultures in the early discovery of drugs.

Regional insights:

Based on regions, North America held the largest market share of about 41.8% of the global 3D cell culture market in the year 2017. This is because of a large number of ongoing research activities in this region, coupled with the availability of sufficient funding for research institutes to opt for relatively costlier technique such as 3D cell culture methods. The countries of the Asia-Pacific region will grow at the highest CAGR in the forecast period owing to rising number of contract research activities, growing focus of pharmaceutical and biotechnological companies on this region for their R&D activities, and increasing awareness among researchers about the benefits of 3D cell culture over 2D methods.

Companies covered:

1. Thermo Fisher Scientific
2. Corning Inc.
3. Lonza Group
4. Merck & Co.
5. InSphero AG
6. Hamilton
7. Kuraray
8. Emulate
9. Mimetas
10. Global Cell Solutions Inc.

Customizations available

The post Global 3D Cell Culture Market (2018-2023) first appeared on CRI Report.

Type segment insights:

The plaque modification devices market is expected to grow the fastest at a rate of 9.0% during the forecast period (2018-2023) owing to its sustainable benefits such as minimizing vessel trauma and reducing plaque burden. With 27% market share, stents contributed the highest revenue share in 2017. Increase in prevalence of CVDs coupled with benefits of stenting, such as rapid return to normalcy, improving blood flow, and brief hospitalization.

End user segment insights:

Hospitals held the largest market share (48%) in 2017. Ambulatory surgical centers (ASCs) are expected to grow at a significant rate of 9.6% during the 2018-2023 period. With accelerated outpatient procedures, the prominence of ASCs is also swelling.

Regional insights:

The global interventional cardiology market can be divided into regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
North America led the global interventional cardiology market with a share of 38% in 2017. Asia-Pacific is expected to expand at a CAGR of 7.6% over 2018–2023. Wide adoption of stents is mostly magnifying the market share.

Companies Covered:

1. Medtronic PLC
2. Boston Scientific Corporation
3. Abbott Laboratories S.A.
4. C. R. Bard, Inc.
5. Johnson & Johnson Pvt. Ltd.
6. Edwards Lifesciences Corporation
7. Terumo Corporation
8. LivaNova, PLC.
9. B. Braun Melsungen AG
10. Teleflex Incorporated
11. MicroPort Medical Apparatus (Shanghai) Co. Ltd.

Customizations available

The post Global Interventional Cardiology Market (2018-2023) first appeared on CRI Report.